舍巴医学中心的随机双盲临床试验：伊维菌素可从本质上降低COVID-19
病毒脱落一项由以色列顶级首席研究员和传染病医师赞助的小型但重要的随机，双盲临床试验
包括使用伊维菌素作为可能的候选药物，以针对目标为100例早发，轻度COVID-19的患者减少病毒脱落并减轻临床恶化。
萨克勒医学院舍巴医学中心地理与热带医学中心主任，
特拉维夫，埃里·施瓦茨教授，
从夏天开始进行这项临床试验。
TrialSite于11月与Schwartz教授进行了交谈，他仍在招募患者。
但是，他最近能够完成研究并在Vimeo上报告了结果。
研究的要点：
伊维菌素可显着降低COVID-19患者的整体病毒脱落。
此外，尽管患者样本的大小不足，但数据确实表明，通常用于治疗寄生虫的药物可以减少感染持续时间。
Professor Eli Schwartz
concludes that more research is needed to capitalize on this promising drug’s potential to significantly impact public health during the pandemic.
For example, the drug shows potential
to treat COVID-19 patients who,for whatever reasons, cannot get vaccinated; and of course, in the developing world where vaccination may be out into the future.
Note that the study results have only been summarized by the Principal investigator and that they must be reviewed by the biomedical scientific community.
TrialSite introduced this important clinical trial originally back on June 15, introducing Dr. Eli Schwartz, the prominent researcher and physician who runs Israel’s only tropical medicine institute.
TrialSite notes that this study
A) hasn’t been peer-reviewed;
B) nor has it been written up and uploaded to pre-print server and that
C) it’s currently only Professor Schwartz summarizing his findings for the world via Vimeo video presentation.
TrialSite qualifies that this study information cannot be considered complete until the results are reviewed by the scientific community.